RECRUITING

POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This multi-centered, randomized controlled trial will evaluate the safety and efficacy of home use of the novel Reia System (RS), which includes the Reia pessary and applicator, compared to standard pessary care (Gellhorn or ring with/without support without knob) among women with stage II-IV pelvic organ prolapse (POP). A total of 182 participants will be recruited among pessary naïve patients who are symptomatic and choose a vaginal pessary for management of their POP from study sites specializing in Urogynecology and Reconstructive Pelvic Surgery (URPS). Participants will be assigned via 1:1 randomization using computer generated numbers in permutated groups of variable block sizes to either the intervention (the Reia System, RS) or standard pessary care (SPC) stratified by site. Participation in this trial will involve a total of four visits over six months. The primary outcome measure will be satisfaction measured at the six-month time point. Secondary outcomes will include validated surveys to assess quality of life, number of self-management events, ease/difficulty of pessary insertion/removal, importance of ability to self-manage pessary, and adverse events. Specific Aims Aim 1: To compare satisfaction with pessary use and management between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 2: To assess successful fitting, number of refitting visits, number of self-management events and continued pessary use over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 3: To compare ease/difficulty of pessary use and importance of ability to self-manage, as well as quality of life over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 4: To measure rates of adverse events and risk factors for adverse events over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary.

Official Title

The POMEGRANATE Trial: A Randomized Controlled Trial Comparing Pessary Home Management of Reia Pessary Versus Standard of Care Pessary for Treatment of Pelvic Organ Prolapse

Quick Facts

Study Start:2024-11-01
Study Completion:2026-10-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06634459

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * English-speaking natal females ≥ 18 years of age
  2. * Willing to self-maintain (insert/remove) pessary
  3. * Pessary naïve with Stage II-IV POP desiring conservative management with a pessary
  4. * Primary indication for use of pessary is treatment of pelvic organ prolapse
  1. * Primary indication for pessary use is for management of stress urinary incontinence
  2. * Prior mesh-augmented prolapse repair (i.e. transvaginal mesh, sacrocolpopexy)
  3. * Short vaginal length (TVL \< 8cm) or subjective vaginal narrowing
  4. * Vaginal fistula (e.g. rectovaginal, vesicovaginal or any type of fistula involving the vagina)
  5. * Vaginal, rectal or bladder malignancy
  6. * Genitourinary infection requiring treatment (See below 1)
  7. * Ongoing treatment for vaginal infections (e.g., chronic bacterial vaginosis) (See below 2)
  8. * Inflammatory bowel disease (Crohn's or ulcerative colitis)
  9. * Pelvic or anorectal chronic pain
  10. * Pelvic floor surgery within the past 6 months or planning to undergo pelvic floor surgery
  11. * Congenital malformation of the bladder, rectum or vagina
  12. * Pregnant or planning pregnancy in the next 6 months
  13. * Prior failure of pessary for POP
  14. * History of hydroureter, hydronephrosis, or impaired renal function secondary to prolapse
  15. 1. Patients with acute vaginal infections will be eligible for enrollment 2 weeks after completing treatment with resolution of symptoms
  16. 2. OK to be on prophylactic/suppressive therapy for HSV

Contacts and Locations

Study Contact

Melissa G Goodwin
CONTACT
202-877-3657
melissa.g.goodwin@medstar.net
Alexis A Dieter
CONTACT
alexis.a.dieter@medstar.net

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35249
United States
Stanford University
Palo Alto, California, 94304
United States
MedStar Health
Washington, District of Columbia, 20010
United States
The University of Chicago
Northbrook, Illinois, 60062
United States
Dartmouth-Hitchcock
Lebanon, New Hampshire, 03756
United States
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87131
United States
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27103
United States
Women & Infants Hospital in Rhode Island
Providence, Rhode Island, 02903
United States
University of Wisconsin
Madison, Wisconsin, 53711
United States

Collaborators and Investigators

Sponsor: Medstar Health Research Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-01
Study Completion Date2026-10-30

Study Record Updates

Study Start Date2024-11-01
Study Completion Date2026-10-30

Terms related to this study

Additional Relevant MeSH Terms

  • Pelvic Organ Prolapse
  • Prolapse